Natixis Advisors LLC Has $44.75 Million Position in HCA Healthcare, Inc. (NYSE:HCA)

Natixis Advisors LLC lifted its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,105 shares of the company’s stock after purchasing an additional 2,459 shares during the quarter. Natixis Advisors LLC’s holdings in HCA Healthcare were worth $44,750,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of HCA. MFA Wealth Advisors LLC acquired a new stake in HCA Healthcare in the 2nd quarter worth about $27,000. Unique Wealth Strategies LLC bought a new stake in HCA Healthcare in the 2nd quarter valued at about $28,000. Bangor Savings Bank boosted its holdings in HCA Healthcare by 112.5% in the 2nd quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares during the period. GPS Wealth Strategies Group LLC boosted its holdings in HCA Healthcare by 284.0% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock valued at $31,000 after purchasing an additional 71 shares during the period. Finally, Capital Performance Advisors LLP bought a new stake in HCA Healthcare in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Insider Buying and Selling

In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the transaction, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the transaction, the executive vice president now directly owns 29,678 shares in the company, valued at $11,438,494.76. This trade represents a 21.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,155 shares of company stock valued at $5,608,990 over the last ninety days. 1.60% of the stock is owned by corporate insiders.

HCA Healthcare Trading Down 0.7 %

HCA opened at $342.96 on Monday. HCA Healthcare, Inc. has a twelve month low of $238.82 and a twelve month high of $417.14. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The company has a fifty day moving average of $385.11 and a 200-day moving average of $357.92. The stock has a market cap of $86.87 billion, a PE ratio of 15.40, a price-to-earnings-growth ratio of 1.32 and a beta of 1.68.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a yield of 0.77%. The ex-dividend date is Friday, December 13th. HCA Healthcare’s dividend payout ratio is presently 11.85%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HCA shares. UBS Group upped their price target on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $392.00 price target on shares of HCA Healthcare in a report on Tuesday, October 1st. Royal Bank of Canada increased their price objective on shares of HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Morgan Stanley initiated coverage on shares of HCA Healthcare in a research note on Tuesday, September 3rd. They issued an “equal weight” rating and a $427.00 price objective for the company. Finally, StockNews.com downgraded shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $385.00.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.